| Diffuse Large B-Cell Lymphoma studied in …STUDIED_INderived200 of 1,150show all (up to 200) |
|---|
| → studied in | NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05952024Phase 2 · recruiting Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06649812Phase 2 · recruiting Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06977711Phase 1 · recruiting Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00006518recruiting Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer · condition mapped ONTOLOGY_EXACT · 1,150 trials mapped (414 active) | — | — | Primary Effusion Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03223610Phase 1/Phase 2 · recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03418038Phase 2 · recruiting Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05006716Phase 1/Phase 2 · recruiting A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05600686Phase 2 · active not recruiting Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,150 trials mapped (414 active) | — | — | Double-Expressor Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06625203active not recruiting A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03349450Phase 2 · completed DPX-Survivac and Checkpoint Inhibitor in DLBCL · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04594642Phase 1 · active not recruiting A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05139017Phase 2/Phase 3 · recruiting A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05907759Phase 2 · recruiting Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Primary Effusion Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06091865Phase 3 · recruiting A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06717347Phase 3 · recruiting A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06929624Phase 3 · active not recruiting A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02992522Phase 1 · active not recruiting Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03015896Phase 1/Phase 2 · completed Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03463057Phase 2 · active not recruiting The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06784167recruiting Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03226704enrolling by invitation Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03628612Phase 2 · enrolling by invitation Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07226843Phase 1 · recruiting A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01829958NA · active not recruiting Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05359211Phase 1 · completed NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04594798Phase 2 · active not recruiting A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05025800Phase 1/Phase 2 · active not recruiting ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05627245Phase 1 · active not recruiting Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06395103Phase 1/Phase 2 · recruiting Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04002947Phase 2 · recruiting Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05757219Phase 2 · recruiting Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04094311Phase 3 · recruiting Study of Out of Specification for Tisagenlecleucel · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07168486Phase 1 · enrolling by invitation CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07817641NA · recruiting Proton Therapy for Mediastinal Lymphoma (PROMLY) · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07818499Phase 1/Phase 2 · not yet recruiting A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04665765Phase 2 · active not recruiting Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05451810Phase 2 · active not recruiting A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05578976Phase 3 · active not recruiting A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05934084NA · recruiting Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06830031Phase 1 · recruiting Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07098364Phase 1/Phase 2 · suspended ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04759586Phase 3 · active not recruiting Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,150 trials mapped (414 active) | — | — | Primary Mediastinal Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05272384Phase 1 · recruiting Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07570017Phase 1 · recruiting A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07814001Phase 2 · not yet recruiting Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03625037Phase 1/Phase 2 · active not recruiting First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04542824Phase 1/Phase 2 · active not recruiting Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04663347Phase 1/Phase 2 · active not recruiting Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04915248Phase 2 · recruiting Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. · condition mapped ONTOLOGY_EXACT · 1,150 trials mapped (414 active) | — | — | Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07225439Phase 1 · recruiting Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07808827Phase 3 · not yet recruiting A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07200375recruiting An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04609046Phase 1 · active not recruiting Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma · condition mapped ONTOLOGY_EXACT · 1,150 trials mapped (414 active) | — | — | Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01961063Phase 1 · active not recruiting Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 1,150 trials mapped (414 active) | — | — | AIDS-Related Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07332507Phase 1 · recruiting Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07502872Phase 2 · not yet recruiting TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05512390Phase 1 · active not recruiting A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06687772Phase 2 · recruiting CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06784726Phase 2 · recruiting Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07365306Phase 2 · recruiting Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04464200Phase 1 · active not recruiting 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05836896Phase 1 · recruiting A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01959698Phase 1 · active not recruiting Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02911142Phase 1/Phase 2 · active not recruiting Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 1,150 trials mapped (414 active) | — | — | Primary Effusion Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06227026Phase 1 · recruiting Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07788118Phase 1/Phase 2 · recruiting A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04742387active not recruiting Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis · condition mapped ONTOLOGY_EXACT · 1,150 trials mapped (414 active) | — | — | Primary Effusion Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05389423Phase 1 · recruiting Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas · condition mapped ONTOLOGY_EXACT · 1,150 trials mapped (414 active) | — | — | Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06536049Phase 1/Phase 2 · recruiting Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06594939Phase 2 · recruiting Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03150329Phase 1 · active not recruiting Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03884998Phase 1 · active not recruiting Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05294731Phase 1/Phase 2 · recruiting Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04007029Phase 1 · active not recruiting Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04104776Phase 1/Phase 2 · recruiting A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06781359recruiting Study on Plasmablastic Lymphoma Patients · condition mapped ONTOLOGY_EXACT · 1,150 trials mapped (414 active) | — | — | Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07588698Phase 2 · not yet recruiting Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07724457Phase 2/Phase 3 · not yet recruiting Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07774234Phase 2 · not yet recruiting Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03943901Phase 2 · active not recruiting Split-Dose R-CHOP for Older Adults With DLBCL · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07735533Phase 1/Phase 2 · not yet recruiting A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03843294Phase 1 · active not recruiting Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07764601NA · not yet recruiting R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06980116Phase 1 · recruiting Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07649304Phase 1 · not yet recruiting AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03440567Phase 1 · completed Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07760610Phase 4 · not yet recruiting Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02889523Phase 1/Phase 2 · active not recruiting Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03136146Phase 2 · recruiting Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05075603Phase 1 · completed Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05887167Phase 1 · recruiting Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06486051Phase 2 · recruiting A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03656835NA · active not recruiting Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05990465Phase 1 · recruiting LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06533579Phase 1/Phase 2 · recruiting Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07749976Phase 1/Phase 2 · not yet recruiting GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07750886recruiting Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06116110recruiting Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07712588Phase 2/Phase 3 · not yet recruiting Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03984448Phase 2/Phase 3 · active not recruiting Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06539195Phase 2 · completed DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07188558Phase 3 · recruiting A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01804686Phase 3 · recruiting A Long-term Extension Study of PCI-32765 (Ibrutinib) · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02443077Phase 3 · active not recruiting Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06323447active not recruiting Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07069699Phase 1/Phase 2 · recruiting Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene · condition mapped ONTOLOGY_EXACT · 1,150 trials mapped (414 active) | — | — | Double-Expressor Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02727803Phase 2 · recruiting Personalized NK Cell Therapy in CBT · condition mapped ONTOLOGY_EXACT · 1,150 trials mapped (414 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03259503Phase 1 · completed Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04263584Phase 2 · completed Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07197307Phase 2 · recruiting Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07609862Phase 1/Phase 2 · recruiting A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05365659Phase 1 · recruiting IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07397832Phase 2 · recruiting CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07654426Phase 2 · recruiting The CARDIOPROTECT Trial · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07729397Phase 1 · not yet recruiting Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30) · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05725720active not recruiting Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07725406Phase 1 · not yet recruiting Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04404283Phase 3 · active not recruiting Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06765317Phase 2 · recruiting A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07494565Phase 2 · recruiting Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05660395Phase 1 · terminated A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05821088Phase 2 · active not recruiting Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06863402Phase 2 · recruiting Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07713459Phase 2 · not yet recruiting A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07714421Phase 1 · not yet recruiting Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05052528Phase 1 · recruiting Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07709624active not recruiting Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01371630Phase 1/Phase 2 · recruiting Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 1,150 trials mapped (414 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05828589Phase 1 · terminated A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07702851Phase 2 · not yet recruiting A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04792489Phase 2 · recruiting DALY II USA/ MB-CART2019.1 for DLBCL · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06043011recruiting Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07599423Phase 2 · not yet recruiting A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05077527Phase 1 · recruiting Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05665062Phase 1 · active not recruiting Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05672251Phase 2 · recruiting Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06015880Phase 1 · recruiting Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04799275Phase 2/Phase 3 · active not recruiting Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06854159Phase 2 · recruiting Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03681535NA · active not recruiting Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04408638Phase 3 · active not recruiting A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06249191Phase 1/Phase 2 · recruiting Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03501576recruiting Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02227251Phase 2 · active not recruiting Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04850495Phase 1 · active not recruiting Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05131022Phase 1 · recruiting A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05660967Phase 2 · terminated Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04836507Phase 1/Phase 2 · recruiting Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05954910recruiting A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07478848Phase 1 · recruiting Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05653271Phase 1 · completed ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06694779completed Thrombosis in Diffuse Large B-cell Lymphoma:the PREDIC-TO (PREDICt ThrOmbosis) Study · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06905509Phase 2 · recruiting Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07676877Phase 1 · not yet recruiting Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05820841Phase 3 · recruiting Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04205409Phase 2 · completed Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01815749Phase 1 · active not recruiting Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 1,150 trials mapped (414 active) | — | — | Adult Grade III Lymphomatoid Granulomatosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04257578Phase 1/Phase 2 · active not recruiting Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04529772Phase 3 · active not recruiting A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07669194not yet recruiting Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03277729Phase 1/Phase 2 · active not recruiting A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04545762Phase 1 · recruiting Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05455697Phase 1/Phase 2 · active not recruiting Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06352242NA · recruiting Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma? · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06898905NA · recruiting Hyperfractionated Dual Equivalent Fractionated Radiation Therapy · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07652476not yet recruiting Neurocognitive Assessment in Long-Term Survivors of Lymphoma · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07507318Phase 2 · recruiting Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05934838Phase 1 · active not recruiting A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01787409NA · active not recruiting Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05453396Phase 2 · terminated Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07647432Phase 2/Phase 3 · not yet recruiting HEME-25: Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV · condition mapped ONTOLOGY_EXACT · 1,150 trials mapped (414 active) | — | — | Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03162536Phase 1/Phase 2 · active not recruiting A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04113226Phase 2 · completed Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06703892Phase 1 · recruiting A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03321643Phase 1 · active not recruiting Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06985576enrolling by invitation Long-term Study to Evaluate Safety and Persistence of GF-CART01 · condition mapped ONTOLOGY_EXACT · 1,150 trials mapped (414 active) | — | — | Primary Mediastinal Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04833114Phase 3 · completed Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04844866Phase 2 · recruiting Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06594640Phase 1/Phase 2 · recruiting R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07638982Phase 1 · not yet recruiting Axatilimab + CAR-T for High-Risk Lymphoma · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05658562Phase 1/Phase 2 · active not recruiting A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03960840Phase 1/Phase 2 · active not recruiting Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04974216Phase 2 · active not recruiting Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06131801recruiting Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06271057Phase 2 · recruiting Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Primary Mediastinal Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07528352Phase 1 · recruiting External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06224309completed Preliminary Assessment of [18F]BL40 in PET/CT Scans · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04139304early Phase 1 · recruiting A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma · condition mapped ONTOLOGY_EXACT · 1,150 trials mapped (414 active) | — | — | Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739813Phase 1 · active not recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05162170completed Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study · condition mapped ONTOLOGY_EXACT · 1,150 trials mapped (414 active) | — | — | Primary Mediastinal Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05412290Phase 1 · active not recruiting Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05663502recruiting Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers · condition mapped ONTOLOGY_EXACT · 1,150 trials mapped (414 active) | — | — | Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05418088Phase 1 · recruiting Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06458439Phase 2 · recruiting Epcoritamab-CAR T Cells for Large B-cell Lymphomas · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07608978Phase 2 · recruiting Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04628494Phase 3 · active not recruiting A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01962636NA · terminated Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04824794Phase 1/Phase 2 · terminated GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies · condition mapped ALIAS · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02362997Phase 2 · completed Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL · condition mapped CURATED_BROADER · 1,150 trials mapped (414 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |